London
· Delayed Price · Currency is GBP · Price in USD UroGen Pharma Statistics
Total Valuation
UroGen Pharma has a market cap or net worth of GBP 344.35 million. The enterprise value is 237.60 million.
| Market Cap | 344.35M |
| Enterprise Value | 237.60M |
Important Dates
The next estimated earnings date is Friday, March 14, 2025.
| Earnings Date | Mar 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +46.48% |
| Shares Change (QoQ) | +17.05% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 32.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 18.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.76 |
| EV / Sales | 3.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.30 |
Financial Position
The company has a current ratio of 9.00, with a Debt / Equity ratio of 4.81.
| Current Ratio | 9.00 |
| Quick Ratio | 8.31 |
| Debt / Equity | 4.81 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.27 |
| Interest Coverage | -6.85 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -21.12% |
| Return on Capital (ROIC) | -50.64% |
| Revenue Per Employee | 307,252 |
| Profits Per Employee | -396,698 |
| Employee Count | 201 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 1.38 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.34% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -29.34% |
| 50-Day Moving Average | 11.49 |
| 200-Day Moving Average | 13.75 |
| Relative Strength Index (RSI) | 39.10 |
| Average Volume (20 Days) | 1,454 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 13.38 |
Income Statement
In the last 12 months, UroGen Pharma had revenue of GBP 66.67 million and -86.08 million in losses. Loss per share was -2.30.
| Revenue | 66.67M |
| Gross Profit | 60.19M |
| Operating Income | -62.47M |
| Pretax Income | -83.07M |
| Net Income | -86.08M |
| EBITDA | -62.14M |
| EBIT | -62.47M |
| Loss Per Share | -2.30 |
Balance Sheet
The company has 186.21 million in cash and 91.58 million in debt, giving a net cash position of 98.09 million.
| Cash & Cash Equivalents | 186.21M |
| Total Debt | 91.58M |
| Net Cash | 98.09M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 19.04M |
| Book Value Per Share | 0.45 |
| Working Capital | 195.71M |
Cash Flow
In the last 12 months, operating cash flow was -71.73 million and capital expenditures -176,080, giving a free cash flow of -71.91 million.
| Operating Cash Flow | -71.73M |
| Capital Expenditures | -176,080 |
| Free Cash Flow | -71.91M |
| FCF Per Share | n/a |
Margins
Gross margin is 90.27%, with operating and profit margins of -93.70% and -129.11%.
| Gross Margin | 90.27% |
| Operating Margin | -93.70% |
| Pretax Margin | -124.59% |
| Profit Margin | -129.11% |
| EBITDA Margin | -93.20% |
| EBIT Margin | -93.70% |
| FCF Margin | n/a |
Dividends & Yields
UroGen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -46.48% |
| Shareholder Yield | -46.48% |
| Earnings Yield | -25.00% |
| FCF Yield | -20.88% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
UroGen Pharma has an Altman Z-Score of -2.04. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.04 |
| Piotroski F-Score | n/a |